For instance, ZNF217 was reported to reduce mRNA m6A methylation in embryonic stem cells and breast cancer cells by sequestering the m6A 'writer' METTL3, thereby supporting embryonic stem cell pluripotency and promoting breast cancer progression 40-43. Here, METTL3 is linked to breast carcinoma.